A rare, life-saving drug developed by Covis and developed by pharmaceutical giant Abbott has been developed by the Indian company and its Australian counterparts to fight a deadly cancer.
The drug, called Covis Bio-Repellent, is one of several drugs developed by Indian company Covis Pharmacovis for the treatment of cancer, a condition known as non-small cell lung cancer.
According to the company, the drug works by targeting a specific type of protein in the cancer cells, called BCL-xL2, which has mutated since the 1960s.
The drug is able to prevent the mutation from spreading into other cells and can even prevent the cells from growing into cancerous cells, allowing it to kill them.
“We have a unique technology which is unique to Covis pharma and our patients,” said Dr Mihir Kaul, CEO of Covis Drug, which is based in India.
“This is a revolutionary drug that will be the life-savers for millions of cancer patients around the world.”
This is an extremely exciting opportunity for the Indian pharmaceutical sector.
In addition, India is a key supplier of drugs to Europe and the rest of the world, including the United States.””
India’s unique pharmacological innovation has been one of the reasons why the country is one in the top 10 countries for pharmaceutical research and development, with over 60 companies active in the sector.”
In addition, India is a key supplier of drugs to Europe and the rest of the world, including the United States.
“Our patients have told us that they feel so much better, and the chemo therapy is helping them live longer,” Dr. Kaul added.
The company has also released an initial clinical trial results from the trial.
The trial was conducted in patients with a rare type of non-Small Cell Lung Cancer (NSCL-CM), a rare form of cancer.
Dr. Kaun said the treatment is the first of its kind and will not only save lives but also reduce the risk of dying from this cancer.
“The first clinical trial is under way.
In the near future, we will conduct a larger trial with more patients, including those with other types of cancer,” he said.”
If we do well in the first trial, we plan to scale it to more patients,” Dr Karun added.
A spokesperson for Covis said they were not able to comment on the clinical trial, which was conducted by a non-profit organisation.
According in a statement, Covis bio-repellent was developed with the goal of providing effective anti-cancer treatment for patients suffering from NSCL-C.
The researchers from Covis had earlier said that their drug, which contains a unique compound called an immunoglobulin (IgG) molecule, is a powerful anti-rejection therapy, meaning it can fight the infection of cancer cells.
The protein-targeting drug was also designed to prevent growth of cancerous tumors.
The new drug is believed to be a key breakthrough for Covs Bio-reject, the company said.
Dr Kaul told Reuters that the new drug could be available to the public in the next two to three years.
According the Indian press, the new cancer drug is an important development for the country, as India is known for being one of India’s fastest-growing economies, with GDP growing by 7.7% in the fourth quarter of last year.